AR043038A1 - Compuestos de pirazolotriazina y usos de los mismos - Google Patents
Compuestos de pirazolotriazina y usos de los mismosInfo
- Publication number
- AR043038A1 AR043038A1 ARP040100365A ARP040100365A AR043038A1 AR 043038 A1 AR043038 A1 AR 043038A1 AR P040100365 A ARP040100365 A AR P040100365A AR P040100365 A ARP040100365 A AR P040100365A AR 043038 A1 AR043038 A1 AR 043038A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- optionally substituted
- members
- partially
- fully saturated
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Obesity (AREA)
- Gynecology & Obstetrics (AREA)
- Cardiology (AREA)
- Pregnancy & Childbirth (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Se describen compuestos que actúan como ligandos de receptor de cannabinoides y sus usos en el tratamiento d enfermedades ligadas a la mediación de los receptores de cannabinoides en animales. También se presentan sus composiciones farmacéuticas y procesos para su preparación. Reivindicación 1: Un compuesto de fórmula (1) caracterizado porque R1 es un arilo opcionalmente sustituido o un heteroarilo opcionalmente sustituido; R2 es un arilo opcionalmente sustituido o un heteroarilo opcionalmente sustituido; R3 es H, alquilo C1-4, alquilo C1-4 sustituido con halo o alcoxi C1-4; R4 es (i) un grupo que tiene la fórmula (2) o fórmula (3) en las que R4a es H o alquilo C1-3; cada R4b y R4b´ es independientemente H, ciano, hidroxi, amino, H2NC(O)-, o un resto químico seleccionado del grupo constituido por alquilo C1-6, alcoxi C1-6, aciloxi, acilo,. Alquil C1-3-O-C(O)-, alquil C1-4-NH-C(O)-, (alquil C1-4)2N-C(O)-, alquil C1-4-amino-, (alquil C1-4)2amino, cicloalquil C3-5amino, acilamino, arilalquil C1-4amino-,heteroarilalquil C1-4amino-, arilo, heteroarilo, un heterociclo parcial o totalmente saturado de 3 a 6 miembros y un anillo carbocíclico parcial o totalmente saturado de 3 a 6 miembros, estando opcionalmente sustituido el resto con uno o más sustituyentes, o R4b o R4b´ tomado conjuntamente con R4e, R4e´ , R4f o R4f´ forma un enlace, un puente metileno o un puente etileno; X es un enlace, -CH2CH2- o -C(R4c)(R4c´)-, siendo cara R3c y R4c´ independientemente H, ciano, hidroxi, amino, H2NC(O)- o un resto químico seleccionado del grupo constituido por alquilo C1-6, alcoxi C1-6, aciloxi, acilo, alquil C1-3-O-C(O)-, alquil C1-4-NH-C(O)-, (alquil C1-4)2N-C(O)-, alquil C1-6aminio-, dialquil C1-4amino-, cicloalquil C23-6amino, acilamino-, arilalquil C1-4amino-, heteroarilalquil C1-4amino-, arilo, heteroarilo, un heterociclo parcial o totalmente saturado de 3 a 6 miembros y un anillo carbocíclico parcial o totalmente saturado de 3 a 6 miembros, estando opcionalmente sustituido dicho resto con uno o más sustituyentes, o R4c o R4c´ tomado conjuntamente con R4e, R4e´, R4f o R4f´ forma un enlace, un puente metileno o un puente etileno; Y es O, S, -C(O)-o -C(R4d)(R4d´), siendo cada R4d y R4d´ independientemente H, ciano, hidroxi, amino, H2NC(O)-, o un resto químico seleccionado del grupo constituido por alquilo C1-6, alcoxi C1-6, aciloxi, acilo, alquil C1-3-O-C(O)-, alquil C1-4-NH-C(O)-, (alquil C1-4)2N-C(O)-, alquil C1-6-amino-, dialquil C1-4-amino-, cicloalquil C3-6amino-, acilamino-, arilalquil C1-4amino-, heteroarilalquil C1-4amino-, arilo, heteroarilo, un heterociclo parcial o totalmente saturado de 3 a 6 miembros y un anillo carbocíclico parcial o totalmente saturado de 3 a 6 miembros, estando opcionalmente sustituido dicho resto con uno o más sustituyentes, o R4d y R4d´ tomados conjuntamente forman un anillo heterocíclico parcial o totalmente saturado de 3 a 6 miembros, un anillo lactona de 5 o 6 miembros o u anillo lactama de 4 a 6 miembros, estando opcionalmente sustituido dicho anillo heterocíclico, dicho anillo lactona y dicho anillo lactama con uno o más sustituyentes, y conteniendo opcionalmente dicho anillo lactona y dicho anillo lactama un heteroátomo adicional seleccionado de O, N o S, o Y es -NR4"-, siendo R4" un H o un resto químico seleccionado del grupo constituido por alquilo C1-6, cicloalquilo C3-6, alquil C1-3sulfonilo-, alquil C1-3aminosulfonilo-, dialquil C1-3aminosulfonilo-, acilo, alquil C1-6-O-C(O)-, arilo y heteroarilo, estando opcionalmente sustituido dicho resto con uno o más sustituyentes; Z es un enlace, -CH2CH2- o -C(R4e)(R4e´)-, siendo cada R4e y R4e´ independientemente H, ciano, amino, H2NC(O)- o un resto químico seleccionado del grupo constituido por alquilo C1-6, alcoxi C1-6, aciloxi, acilo, alquil C1-3-O-C(O)-, alquil C1-4-NH-C(O)-, (alquil C1-4)2N-C(O)-, alquil C1-6amino-, dialquil C1-4amino-, cicloalquil C3-6amino-, acilamino-, arilalquil C1-4amino-, heteroarilalquil C1-4amino-, arilo, heteroarilo, un heterociclo parcial o totalmente saturado de 3 a 6 miembros y un anillo carbocíclico parcial o totalmente saturado de 3 a 6 miembros, estando opcionalmente sustituido dicho resto con uno o más sustituyentes, o R4e y R4e´ tomado conjuntamente con R4b, R4b´, R4c o R4c´ forman un enlace, un puente metileno o un puente etileno; y cada R4f y R4f´ es independientemente H, ciano, hidroxi, amino, H2NC(O)- o un resto químico seleccionado del grupo constituido por alquilo C1-6, alcoxi C1-6, aciloxi, acilo, alquil C1-3-O-C(O)-, alquil C1-4-NH-C(O)-, (alquil C1-4)2N-C(O)-, alquil C1-6amino-, dialquil C1-4amino-, cicloalquil C3-6amino-, acilamino-, arilalquil C1-4amino-, heteroarilalquil C1-4amino-, arilo, heteroarilo, un heterociclo parcial o totalmente saturado de 3 a 6 miembros y un anillo carbocíclico parcial o totalmente saturado de 3 a 6 miembros, estando opcionalmente sustituido dicho resto con uno o más sustituyentes, o R4f o R4f´ tomados conjuntamente con Rb, R4b´, R4c o R4c´ forma un enlace, un puente metileno o un puente etileno; (ii) un grupo que tiene la fórmula (4) en la que cada R5 y R6 es independientemente H o alquilo C1-4, y R7 es un alquilo C1-4 opcionalmente sustituido, o un anillo heterocíclico parcial o totalmente saturado de 4 a 6 miembros opcionalmente sustituido que contiene de 1 a 2 heteroátomos independientemente seleccionados de O, S o N, o R5 y R6 o R5 y R7 tomados conjuntamente forman una lactona de 5 o 6 miembros, una lactama de 4 a 6 miembros o un heterociclo parcial o totalmente saturado de 4 a 6 miembros que contiene de 1 a 2 heteroátomos independientemente seleccionados de O, S, o N, estando opcionalmente sustituidos dicha lactona, dicha lactama y dicho heterociclo con uno o más sustituyentes; o (iii) un grupo amino que tiene unido al mismo al menos un resto químico seleccionado del grupo constituido por alquilo C1-8, arilalquilo C1-4, un cicloalquilo C3-8 parcial o totalmente saturado, hidroxialquilo C1-6, alcoxi C1-3-alquilo C1-6, heteroarilalquilo C1-3, arilo, heteroarilo y un heterociclo total o parcialmente saturado, estando dicho resto opcionalmente sustituido con uno o más sustituyentes y a condición de que R4 no es n-butilamina o dietilamina cuando R1 sea fenilo, ?-tolilo o p-metoxifenilo, y R2 sea fenilo o m-tolilo; una sal farmacéuticamente aceptable del mismo, un profármaco de dicho compuesto o dicha sal, o un solvato o hidrato de dicho compuesto, dicha sal o dicho profármaco.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44572803P | 2003-02-06 | 2003-02-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR043038A1 true AR043038A1 (es) | 2005-07-13 |
Family
ID=32851000
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040100365A AR043038A1 (es) | 2003-02-06 | 2004-02-05 | Compuestos de pirazolotriazina y usos de los mismos |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US7329658B2 (es) |
| EP (1) | EP1592691A1 (es) |
| JP (1) | JP4018736B2 (es) |
| KR (1) | KR20050099531A (es) |
| CN (1) | CN1768061A (es) |
| AP (1) | AP2005003368A0 (es) |
| AR (1) | AR043038A1 (es) |
| AU (1) | AU2004209447A1 (es) |
| BR (1) | BRPI0406957A (es) |
| CA (1) | CA2513409A1 (es) |
| CL (1) | CL2004000182A1 (es) |
| CR (1) | CR7932A (es) |
| EA (1) | EA200501253A1 (es) |
| EC (1) | ECSP055945A (es) |
| GT (1) | GT200400013A (es) |
| HR (1) | HRP20050659A2 (es) |
| IS (1) | IS7936A (es) |
| MA (1) | MA27652A1 (es) |
| MX (1) | MXPA05007562A (es) |
| NL (1) | NL1025404C2 (es) |
| NO (1) | NO20054082L (es) |
| OA (1) | OA12980A (es) |
| PE (1) | PE20040946A1 (es) |
| PL (1) | PL379009A1 (es) |
| TN (1) | TNSN05190A1 (es) |
| TW (1) | TWI260223B (es) |
| UY (1) | UY28178A1 (es) |
| WO (1) | WO2004069837A1 (es) |
| ZA (1) | ZA200506255B (es) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60316829T2 (de) * | 2002-08-02 | 2008-07-10 | Merck & Co., Inc. | Substituierte furo[2,3-b]pyridin-derivate |
| US7176210B2 (en) | 2003-02-10 | 2007-02-13 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
| US7141669B2 (en) * | 2003-04-23 | 2006-11-28 | Pfizer Inc. | Cannabiniod receptor ligands and uses thereof |
| US20040214856A1 (en) * | 2003-04-23 | 2004-10-28 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
| US7268133B2 (en) | 2003-04-23 | 2007-09-11 | Pfizer, Inc. Patent Department | Cannabinoid receptor ligands and uses thereof |
| US7145012B2 (en) | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
| WO2004099157A1 (en) * | 2003-05-07 | 2004-11-18 | Pfizer Products Inc. | Cannabinoid receptor ligands and uses thereof |
| US20040224962A1 (en) * | 2003-05-09 | 2004-11-11 | Pfizer Inc | Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss |
| US7232823B2 (en) * | 2003-06-09 | 2007-06-19 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
| US20050026983A1 (en) * | 2003-07-30 | 2005-02-03 | Pfizer Inc | Imidazole compounds and uses thereof |
| US20050043327A1 (en) * | 2003-08-21 | 2005-02-24 | Pfizer Inc | Pharmaceutical composition for the prevention and treatment of addiction in a mammal |
| US7151097B2 (en) * | 2003-11-07 | 2006-12-19 | Pfizer Inc. | Bicyclic pyrazolyl and imidazolyl compounds and uses thereof |
| WO2005049615A1 (en) * | 2003-11-21 | 2005-06-02 | Pfizer Products Inc. | Pyrazolo`1,5-a!`1,3,5! triazin -4-one derivatives as cb1 receptor antagonists |
| US7649002B2 (en) | 2004-02-04 | 2010-01-19 | Pfizer Inc | (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists |
| US7262318B2 (en) * | 2004-03-10 | 2007-08-28 | Pfizer, Inc. | Substituted heteroaryl- and phenylsulfamoyl compounds |
| US20050288340A1 (en) * | 2004-06-29 | 2005-12-29 | Pfizer Inc | Substituted heteroaryl- and phenylsulfamoyl compounds |
| PA8660701A1 (es) | 2005-02-04 | 2006-09-22 | Pfizer Prod Inc | Agonistas de pyy y sus usos |
| WO2006129193A2 (en) * | 2005-05-27 | 2006-12-07 | Pfizer Products Inc. | Combination of a cannabinoid-1- receptor-antagonist and a microsomal triglyceride transfer protein inhibitor for treating obesity or mainataining weight loss |
| US7923465B2 (en) | 2005-06-02 | 2011-04-12 | Glenmark Pharmaceuticals S.A. | Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation |
| JP2008545739A (ja) | 2005-06-02 | 2008-12-18 | グレンマーク・ファーマシューティカルズ・エスエー | 新規なカンナビノイド受容体リガンド、それらを含む薬剤組成物、およびそれらの調製方法 |
| WO2006131807A1 (en) * | 2005-06-06 | 2006-12-14 | Pfizer Products Inc. | Preparation of 3-amino-4,5-disubstituted-pyrazole derivatives |
| JP2008545009A (ja) | 2005-06-30 | 2008-12-11 | プロシディオン・リミテッド | Ｇｐｃｒアゴニスト |
| JP4847275B2 (ja) * | 2005-10-21 | 2011-12-28 | 田辺三菱製薬株式会社 | ピラゾロ［１，５−ａ］ピリミジン化合物 |
| US7741317B2 (en) | 2005-10-21 | 2010-06-22 | Bristol-Myers Squibb Company | LXR modulators |
| US7888376B2 (en) | 2005-11-23 | 2011-02-15 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
| DK1989196T3 (da) | 2006-02-23 | 2013-04-15 | Pfizer Ltd | Piperidinoylpyrrolidiner som melanocortin-type 4-receptoragonister |
| TW201345908A (zh) * | 2006-07-05 | 2013-11-16 | Mitsubishi Tanabe Pharma Corp | 吡唑并〔１，５-ａ〕嘧啶化合物 |
| WO2008059335A1 (en) | 2006-11-13 | 2008-05-22 | Pfizer Products Inc. | Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof |
| KR100808241B1 (ko) * | 2006-11-21 | 2008-03-03 | 윤성화 | Ｃｂ1에 길항 활성을 갖는 1ｈ-파이라졸-3-옥심카바메이트화합물 유도체 |
| WO2008070496A2 (en) | 2006-12-01 | 2008-06-12 | Bristol-Myers Squibb Company | N- ( (3-benzyl) -2, 2- (bis-phenyl) -propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases |
| WO2008081204A1 (en) | 2007-01-04 | 2008-07-10 | Prosidion Limited | Piperidine gpcr agonists |
| US20100048625A1 (en) | 2007-01-04 | 2010-02-25 | Matthew Colin Thor Fyfe | Piperidine gpcr agonists |
| CL2008000018A1 (es) | 2007-01-04 | 2008-08-01 | Prosidion Ltd | Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci |
| GB0700122D0 (en) | 2007-01-04 | 2007-02-14 | Prosidion Ltd | GPCR agonists |
| PE20081849A1 (es) | 2007-01-04 | 2009-01-26 | Prosidion Ltd | Derivados de piperidin-4-il-propoxi-benzamida como agonistas de gpcr |
| PE20090142A1 (es) * | 2007-04-11 | 2009-02-19 | Merck & Co Inc | Derivados de furo[2,3-b] piridina sustituidos como moduladores del receptor canabinoide-1 |
| JP4837701B2 (ja) * | 2007-04-20 | 2011-12-14 | 田辺三菱製薬株式会社 | 医薬組成物 |
| GB0720389D0 (en) | 2007-10-18 | 2008-11-12 | Prosidion Ltd | G-Protein Coupled Receptor Agonists |
| GB0720390D0 (en) | 2007-10-18 | 2007-11-28 | Prosidion Ltd | G-Protein coupled receptor agonists |
| SG176464A1 (en) * | 2008-05-09 | 2011-12-29 | Agency Science Tech & Res | Diagnosis and treatment of kawasaki disease |
| JP5530438B2 (ja) | 2008-08-06 | 2014-06-25 | ファイザー・リミテッド | Ｍｃ４作動薬としてのジアゼピンおよびジアゾカン化合物 |
| WO2012138945A1 (en) * | 2011-04-08 | 2012-10-11 | Aestus Therapeutics, Inc. | Methods of treating schizophrenia with pyrazole derivative inhibitors of tgf - beta |
| US8871754B2 (en) | 2012-11-19 | 2014-10-28 | Irm Llc | Compounds and compositions for the treatment of parasitic diseases |
| ME03042B (me) | 2012-11-19 | 2018-10-20 | Novartis Ag | Jedinjenja i kompozicije za tretman parazitskih oboljenja |
| WO2019154294A1 (zh) * | 2018-02-06 | 2019-08-15 | 江苏恒瑞医药股份有限公司 | 吡唑并[1,5-a][1,3,5]三嗪-2-胺类衍生物、其制备方法及其在医药上的应用 |
| CN110551133A (zh) * | 2019-07-23 | 2019-12-10 | 上海合全药业股份有限公司 | 叔丁基-5-(羟甲基)-7-氧杂-2-氮杂螺[3.5]壬烷-2-甲酸基酯的制法 |
| CN112500416B (zh) * | 2019-07-30 | 2021-12-17 | 厦门宝太生物科技股份有限公司 | 一种吡唑并三嗪类化合物中间体的制备方法 |
| TWI794742B (zh) | 2020-02-18 | 2023-03-01 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| JP7429799B2 (ja) | 2020-02-18 | 2024-02-08 | ギリアード サイエンシーズ， インコーポレイテッド | 抗ウイルス化合物 |
| TWI775313B (zh) | 2020-02-18 | 2022-08-21 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| EP4323362A1 (en) | 2021-04-16 | 2024-02-21 | Gilead Sciences, Inc. | Methods of preparing carbanucleosides using amides |
| CA3228162A1 (en) | 2021-08-18 | 2023-02-23 | Gilead Sciences, Inc. | Phospholipid compounds and methods of making and using the same |
Family Cites Families (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US574491A (en) * | 1897-01-05 | Brake-beam | ||
| US3865824A (en) | 1972-03-07 | 1975-02-11 | Icn Pharmaceuticals | 2-Aryl-7-substituted pyrazolo {8 1,5{i a{b {9 1,3,5-triazines |
| US3910907A (en) | 1973-07-09 | 1975-10-07 | Icn Pharmaceuticals | Pyrazolo(1,5-a)-1,3,5-triazines |
| US3995039A (en) | 1975-05-27 | 1976-11-30 | Merck & Co., Inc. | Pyrazolo [1,5-a] [1,3,5] triazines |
| CH635587A5 (fr) | 1978-01-09 | 1983-04-15 | Aron Sa | Derives amines de pyrazolo (1,5-a) s.triazine, therapeutiquement actifs et leurs procedes de preparation. |
| US4767858A (en) | 1985-06-06 | 1988-08-30 | Biomeasure, Incorporated | Anti-arthritic pyrazolo-triazine derivatives |
| US4734414A (en) | 1985-06-06 | 1988-03-29 | Biomeasure, Inc. | Anti-inflammatory and anti-arthritic pyrazolo-[1,5-a]-1,3,5-triazine derivatives, compositions, and method of use therefor |
| GB8613591D0 (en) | 1986-06-04 | 1986-07-09 | Roussel Lab Ltd | Chemical compounds |
| EP0268554B1 (de) | 1986-10-22 | 1991-12-27 | Ciba-Geigy Ag | 1,5-Diphenylpyrazol-3-carbonsäurederivate zum Schützen von Kulturpflanzen |
| US4824834A (en) | 1986-10-31 | 1989-04-25 | Otsuka Pharmaceutical Company, Limited | Pyrazolotriazine compounds |
| US5051518A (en) | 1987-05-29 | 1991-09-24 | Ortho Pharmaceutical Corporation | Pharmacologically active 2- and 3-substituted (1',5'-diaryl-3-pyrazolyl)-N-hydroxypropanamides |
| AU611437B2 (en) | 1987-05-29 | 1991-06-13 | Ortho Pharmaceutical Corporation | Pharmacologically active 2- and 3-substituted (1',5'-diaryl-3-pyrazolyl)-n-hydroxypropanamides and method for synthesizing the same |
| JPH0276880A (ja) | 1988-06-16 | 1990-03-16 | Sankyo Co Ltd | 悪液質改善治療剤 |
| CA1330079C (en) | 1988-10-13 | 1994-06-07 | Michihiko Tsujitani | Pyrrolo (3,2-e)pyrazolo(1,5-a)pyrimidine derivative and medicine comprising the same |
| JP2691317B2 (ja) | 1989-08-25 | 1997-12-17 | 株式会社大塚製薬工場 | ４―ヒドロキシ―８―（３―低級アルコキシ―４―フェニルスルフィニルフェニル）ピラゾロ〔１，５―ａ〕―１，３，５―トリアジン光学活性体の塩類及びその製造方法 |
| PH27357A (en) | 1989-09-22 | 1993-06-21 | Fujisawa Pharmaceutical Co | Pyrazole derivatives and pharmaceutical compositions comprising the same |
| EP0459702A1 (en) | 1990-05-29 | 1991-12-04 | Zeneca Limited | Azole Derivatives |
| US5356894A (en) | 1990-05-29 | 1994-10-18 | Rodney Peter W | Morpholinyl substituted [1,2,4]-triazolo[1,5-a]triazine as antagonist |
| FR2665898B1 (fr) | 1990-08-20 | 1994-03-11 | Sanofi | Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| KR927003595A (ko) | 1990-10-09 | 1992-12-18 | 오츠카 아키히코 | 피리미딘 유도체, 이의 제조방법 및 안드로겐 저해제 |
| GB9111130D0 (en) | 1991-05-23 | 1991-07-17 | Ici Plc | Azole derivatives |
| GB9111131D0 (en) | 1991-05-23 | 1991-07-17 | Ici Plc | Heterocyclic compounds |
| GB9125002D0 (en) | 1991-11-25 | 1992-01-22 | Ici Plc | Azole derivatives |
| FR2692575B1 (fr) | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| US5571813A (en) | 1993-06-10 | 1996-11-05 | Beiersdorf-Lilly Gmbh | Fused pyrimidine compounds and their use as pharmaceuticals |
| FR2714057B1 (fr) | 1993-12-17 | 1996-03-08 | Sanofi Elf | Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant. |
| US5596106A (en) | 1994-07-15 | 1997-01-21 | Eli Lilly And Company | Cannabinoid receptor antagonists |
| FR2741621B1 (fr) | 1995-11-23 | 1998-02-13 | Sanofi Sa | Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant |
| FR2742148B1 (fr) | 1995-12-08 | 1999-10-22 | Sanofi Sa | Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant |
| US6060478A (en) | 1996-07-24 | 2000-05-09 | Dupont Pharmaceuticals | Azolo triazines and pyrimidines |
| US6191131B1 (en) | 1997-07-23 | 2001-02-20 | Dupont Pharmaceuticals Company | Azolo triazines and pyrimidines |
| US6313124B1 (en) | 1997-07-23 | 2001-11-06 | Dupont Pharmaceuticals Company | Tetrazine bicyclic compounds |
| US6124289A (en) | 1996-07-24 | 2000-09-26 | Dupont Pharmaceuticals Co. | Azolo triazines and pyrimidines |
| ES2294800T3 (es) | 1996-07-24 | 2008-04-01 | Bristol-Myers Squibb Pharma Company | Azolo triazinas y pirimidinas. |
| CA2278307A1 (en) | 1997-01-21 | 1998-07-23 | Siegfried Benjamin Christensen Iv | Novel cannabinoid receptor modulators |
| FR2758723B1 (fr) | 1997-01-28 | 1999-04-23 | Sanofi Sa | Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments |
| FR2761266B1 (fr) | 1997-03-28 | 1999-07-02 | Sanofi Sa | Composition pharmaceutique formee par granulation humide pour l'administration orale d'un derive du n-piperidino-3- pyrazolecarboxamide, de ses sels et de leurs solvates |
| IL137019A (en) | 1998-01-28 | 2010-11-30 | Du Pont Pharm Co | 2,7 - dimethyl - 4 - (substituted amino) - 8 - arylpyrazolo [1,5-a] triazine derivatives and pharmaceutical compositions containing them |
| US6194410B1 (en) | 1998-03-11 | 2001-02-27 | Hoffman-La Roche Inc. | Pyrazolopyrimidine and pyrazolines and process for preparation thereof |
| US6509338B1 (en) | 1998-06-22 | 2003-01-21 | Bristol-Myers Squibb Company | Pyrazolo[1,5-A]triazine corticotropin releasing factor antagonists |
| FR2783246B1 (fr) | 1998-09-11 | 2000-11-17 | Aventis Pharma Sa | Derives d'azetidine, leur preparation et les medicaments les contenant |
| IL141769A0 (en) | 1998-09-11 | 2002-03-10 | Aventis Pharma Sa | Azetidine derivatives, preparation and medicines containing them |
| FR2789079B3 (fr) | 1999-02-01 | 2001-03-02 | Sanofi Synthelabo | Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant |
| WO2001023388A2 (en) | 1999-09-30 | 2001-04-05 | Neurogen Corporation | AMINO SUBSTITUTED PYRAZOLO[1,5,-a]-1,5-PYRIMIDINES AND PYRAZOLO[1,5-a]-1,3,5-TRIAZINES |
| IL148905A0 (en) | 1999-09-30 | 2002-09-12 | Neurogen Corp Pfizer Inc | Certain alkylene diamine-substituted pyrazolo{1,5,-a}-1,5-pyrimidines and pyrazolo{1,5,-a}-1,3,5-triazines |
| FR2799124B1 (fr) | 1999-10-01 | 2004-08-13 | Sanofi Synthelabo | Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments |
| JP2003512326A (ja) | 1999-10-18 | 2003-04-02 | ユニヴァーシティ オブ コネチカット | カンナビノイド相似インドール誘導体 |
| MXPA02005100A (es) | 1999-10-18 | 2003-09-25 | Alexipharma Inc | Derivados de pirazol antagonistas de receptor de canabinoide. |
| FR2800375B1 (fr) | 1999-11-03 | 2004-07-23 | Sanofi Synthelabo | Derives tricycliques d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant |
| FR2800372B1 (fr) | 1999-11-03 | 2001-12-07 | Sanofi Synthelabo | Derives tricycliques d'acide 1-benzylpyrazole-3- carboxylique, leur preparation, les medicaments en contenant |
| FR2804604B1 (fr) | 2000-02-09 | 2005-05-27 | Sanofi Synthelabo | Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac |
| EP1254115A2 (en) | 2000-02-11 | 2002-11-06 | Bristol-Myers Squibb Company | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases |
| US6479479B2 (en) | 2000-03-03 | 2002-11-12 | Aventis Pharma S.A. | Azetidine derivatives, their preparation and pharmaceutical compositions containing them |
| US6355631B1 (en) | 2000-03-03 | 2002-03-12 | Aventis Pharma S.A. | Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and their preparation |
| US6566356B2 (en) | 2000-03-03 | 2003-05-20 | Aventis Pharma S.A. | Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation |
| PT1268435E (pt) | 2000-03-23 | 2007-02-28 | Solvay Pharm Bv | Derivados de 4,5-diidro-1h-pirazol tendo actividade cb1-antagonista |
| FR2809621B1 (fr) | 2000-05-12 | 2002-09-06 | Sanofi Synthelabo | Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles comme antidiarrheiques |
| US20020019421A1 (en) | 2000-07-05 | 2002-02-14 | Roni Biberman | Compositions and therapy for substance addiction |
| FR2814678B1 (fr) * | 2000-10-04 | 2002-12-20 | Aventis Pharma Sa | Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite |
| US20020091114A1 (en) | 2000-10-04 | 2002-07-11 | Odile Piot-Grosjean | Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity |
| DK1354884T3 (da) | 2000-12-28 | 2008-03-03 | Ono Pharmaceutical Co | Cyklopenta[d]pyrazolo[1,5-a]pyrimidinforbindelse som CRF-receptorantagonist |
| BR0208357A (pt) | 2001-03-13 | 2004-06-29 | Bristol Myers Squibb Pharma Co | Composto, composição farmacêutica, método de antagonização de um receptor de fator de liberação de corticotropina (crf), método de tratamento de disfunção, método de triagem de ligantes, método de detecção de receptores de crf, método de inibição da ligação de crf, artigo industrializado e usos do composto |
| JP4373675B2 (ja) | 2001-03-22 | 2009-11-25 | ソルベイ・フアーマシユーチカルズ・ベー・ブイ | Ｃｂ１−拮抗活性を有する４，５−ジヒドロ−１ｈ−ピラゾール誘導体 |
| ITMI20011483A1 (it) | 2001-07-11 | 2003-01-11 | Res & Innovation Soc Coop A R | Uso di composti come antagonisti funzionali ai recettori centrali deicannabinoidi |
| AU2002319627A1 (en) | 2001-07-20 | 2003-03-03 | Merck And Co., Inc. | Substituted imidazoles as cannabinoid receptor modulators |
| FR2829028B1 (fr) | 2001-08-29 | 2004-12-17 | Aventis Pharma Sa | Association d'un antagoniste du recepteur cb1 et d'un produit qui active la neurotransmission dopaminergique dans le cerveau, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de |
| FR2829027A1 (fr) | 2001-08-29 | 2003-03-07 | Aventis Pharma Sa | Association avec un antagoniste du recepteur cb1, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de parkinson |
| JP2005507875A (ja) | 2001-08-31 | 2005-03-24 | ユニバーシティ オブ コネチカット | カンナビノイド受容体に作用する新規なピラゾール類似体 |
| PT1429761E (pt) | 2001-09-21 | 2007-02-28 | Solvay Pharm Bv | Novos derivados de 4,5-di-hidro-1h-pirazol tendo uma actividade cb1-antagonística |
| US6974810B2 (en) | 2001-09-21 | 2005-12-13 | Solvay Pharmaceuticals B.V. | 4,5-Dihydro-1H-pyrazole derivatives having potent CB1-antagonistic activity |
| US6509367B1 (en) | 2001-09-22 | 2003-01-21 | Virginia Commonwealth University | Pyrazole cannabinoid agonist and antagonists |
| US20040267028A1 (en) | 2001-09-24 | 2004-12-30 | Smith Roger A | Preparation and use of pyrrole derivatives for treating obesity |
| US20030139386A1 (en) | 2001-12-21 | 2003-07-24 | Sophie Cote | Pharmaceutical compositions based on azetidine derivatives |
| ES2245772T3 (es) | 2002-03-07 | 2006-01-16 | Smithkline Beecham Corporation | Derivados de pirazolopirimidina y pirazolotriazina y composiciones farmaceuticas que los contienen. |
| US6825209B2 (en) | 2002-04-15 | 2004-11-30 | Research Triangle Institute | Compounds having unique CB1 receptor binding selectivity and methods for their production and use |
| CA2502511A1 (en) | 2002-10-18 | 2004-05-29 | Pfizer Products Inc. | Cannabinoid receptor ligands and uses thereof |
| US7129239B2 (en) | 2002-10-28 | 2006-10-31 | Pfizer Inc. | Purine compounds and uses thereof |
| US7247628B2 (en) | 2002-12-12 | 2007-07-24 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
| TWI290500B (en) * | 2004-12-14 | 2007-12-01 | Arima Optoelectronics Corp | Laser dicing apparatus for a silicon wafer and dicing method thereof |
-
2004
- 2004-01-21 US US10/763,105 patent/US7329658B2/en not_active Expired - Fee Related
- 2004-01-26 EP EP04705138A patent/EP1592691A1/en not_active Withdrawn
- 2004-01-26 MX MXPA05007562A patent/MXPA05007562A/es unknown
- 2004-01-26 PL PL379009A patent/PL379009A1/pl not_active Application Discontinuation
- 2004-01-26 CA CA002513409A patent/CA2513409A1/en not_active Abandoned
- 2004-01-26 CN CNA2004800091255A patent/CN1768061A/zh active Pending
- 2004-01-26 JP JP2006500314A patent/JP4018736B2/ja not_active Expired - Fee Related
- 2004-01-26 EA EA200501253A patent/EA200501253A1/ru unknown
- 2004-01-26 WO PCT/IB2004/000269 patent/WO2004069837A1/en active Application Filing
- 2004-01-26 KR KR1020057014432A patent/KR20050099531A/ko active IP Right Grant
- 2004-01-26 AP AP2005003368A patent/AP2005003368A0/xx unknown
- 2004-01-26 OA OA1200500215A patent/OA12980A/en unknown
- 2004-01-26 BR BR0406957-9A patent/BRPI0406957A/pt not_active IP Right Cessation
- 2004-01-26 AU AU2004209447A patent/AU2004209447A1/en not_active Abandoned
- 2004-02-03 PE PE2004000124A patent/PE20040946A1/es not_active Application Discontinuation
- 2004-02-03 CL CL200400182A patent/CL2004000182A1/es unknown
- 2004-02-04 UY UY28178A patent/UY28178A1/es not_active Application Discontinuation
- 2004-02-04 NL NL1025404A patent/NL1025404C2/nl not_active IP Right Cessation
- 2004-02-05 AR ARP040100365A patent/AR043038A1/es unknown
- 2004-02-05 TW TW093102638A patent/TWI260223B/zh not_active IP Right Cessation
- 2004-02-06 GT GT200400013A patent/GT200400013A/es unknown
-
2005
- 2005-07-11 IS IS7936A patent/IS7936A/is unknown
- 2005-07-19 HR HR20050659A patent/HRP20050659A2/hr not_active Application Discontinuation
- 2005-08-02 EC EC2005005945A patent/ECSP055945A/es unknown
- 2005-08-04 CR CR7932A patent/CR7932A/es not_active Application Discontinuation
- 2005-08-04 ZA ZA200506255A patent/ZA200506255B/en unknown
- 2005-08-05 TN TNP2005000190A patent/TNSN05190A1/fr unknown
- 2005-08-05 MA MA28421A patent/MA27652A1/fr unknown
- 2005-09-02 NO NO20054082A patent/NO20054082L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR043038A1 (es) | Compuestos de pirazolotriazina y usos de los mismos | |
| AR041835A1 (es) | Compuestos de purina y usos de los mismos | |
| AR053232A1 (es) | Derivados de piridina condensadas, composiciones farmaceuticas que los contienen y su empleo en la fabricacion de agentes terapeuticos antiinflamatorios y para el tratamiento de enfermedades relacionadas con el sistema inmunologico. | |
| AR048495A1 (es) | Benzoil amino heterociclicos, utiles para el tratamiento de enfermadades intermediadas por glk | |
| AR051202A1 (es) | Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa | |
| AR039399A1 (es) | Compuestos quimicos con actividad doble, procedimientos para su preparacion y composiciones farmaceuticas | |
| AR044539A1 (es) | Ligandos de receptores de canabinoides y sus usos | |
| AR049126A1 (es) | Derivados de 5, 6, 7, 8 - tetrahidroimidazo[1,5a]piridina con actividad inhibitoria de la aldosterona sintasa, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento del hiperaldosterismo y del sindrome de cushing. | |
| AR032624A1 (es) | Derivados de fenilamina ciclica, uso de los mismos para la fabricacion de medicamentos y composicion farmaceutica | |
| AR036093A1 (es) | Compuestos derivados de tiazolidinilo, pirrolidinilo, oxazolidinilo, piperidilo, morfolinilo y tiomorfolinilo, su uso, composiciones farmaceuticas que los comprenden, y compuestos intermediarios | |
| AR038341A1 (es) | Compuestos que son agonistas de receptores alfa-1 preferentemente agonistas de receptores alfa-1a/l | |
| AR054365A1 (es) | Derivados de heteroaril benzamidas, composiciones farmaceuticas que los contienen, usos en enfermedades mediadas por glucoquinasasy metodo de preparacion de los mismos. | |
| JP2006517220A5 (es) | ||
| AR045595A1 (es) | Composiciones utiles como inhibidores de proteinas quinasas | |
| ES2623982T3 (es) | Compuestos heterocíclicos de unión a receptor de quimiocina con eficacia potenciada | |
| AR038536A1 (es) | N-aril-2-oxazolidinona-5- carboxamidas y sus derivados | |
| AR047901A1 (es) | Inhibidores de proteasa ns3 del virus de la hepatitis c | |
| ECSP034865A (es) | Resolución óptica de (1-benzilo-4-metilopiperidina-3-il)-metilamina y su uso para la preparación de derivados de pirrolo 2,3-pirimidina como inhibidores de proteina quinasas | |
| AR044078A1 (es) | Dihidroquinazolinas sustituidas | |
| AR051091A1 (es) | Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa | |
| AR051090A1 (es) | Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa | |
| AR054982A1 (es) | Compuestos de piperidinilamino-tieno [2,3-d] pirimidina | |
| AR054214A1 (es) | Compuestos derivados de 1, 1 - dioxotiadiazina, composiciones farmaceuticas que los contienen y su uso en el tratamiento de la infeccion por el virus de la hepatitis c. | |
| AR067996A1 (es) | Derivados heterociclicos de ciclopropano,composiciones farmaceuticas que los contienen y usos de los mismos para el tratamiento de afecciones asociadas a receptores de histamina h3, tales como enfermedad de alzheimer y esquizofrenia,entre otros. | |
| CO6190513A2 (es) | Compuestos tetrahidrociclopenta [b] indol como moduladores del receptor de androgenos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |